Drug Testing Debate – Parenting Mag 4 Pt. Series Tue, 22 Oct 2002 Parenting Magazine published a 5-part report about the impact on children of FDA’s “The Pediatric Rule.” That Rule provides drug companies six month patent extension on drugs tested in children. This financial windfall could translate into some…
Human Pesticide Experiments “Allowing human experiments, such as those conducted recently in the United Kingdom, to serve as the basis for registering pesticides, is ethically indefensible.” Ken Cook, President Environmental Working Group January 8, 2003 "Should the EPA Accept Human Pesticide Experiments?", testimony by Vera Hassner Sharav before the Committee…
Guidant Didn’t Disclose a Flaw in Defibrillator for 3 Years_NYT / FDA Wrong on Crestor Safety Tue, 24 May 2005 The New York Times reports that the maker a a heart defirillator knew for 3 years about a malfunction and failed to inform physicians about It because the company “had…
Psychopharmacology in Turmoil: David Healy, MD Presentation Columbia + Debate Dr. Joseph Coyne, Ph.D Fri, 9 Dec 2005 Recent reports describing a determined effort to pathologize US infants and toddlers who are being declared to suffer from “severe mental disorders”–the latest, most aggressively marketed diagnosis for children is Bipolar disorder,…
Petition FDA to Investigate if SSRI Induced School Shootings Fri, 25 Mar 2005 The Minnesota shooting rampage by 16-year old Jeff Weise, prompted the parent organization, Ablechild.org, to petition the FDA to conduct “a full investigation into the possible SSRI induced school shootings.” “It took 15 years for the FDA…
WSJ: Debate Over Antidepressants: FDA role in suppressing damaging data Tue, 25 May 2004 How were drug manufacturers able to conceal vital evidence of harmful antidepressant drug effects? The answer is becoming clearer by the day: federal regulators and the psychiatrists who tested these drugs in clinical trials are invested…
Conflicts of Interest policy – New York Times Sun, 28 Mar 2004 To: ‘Executive-editor@nytimes’; ‘gcollins@nytimes’; ‘arosenthal@nytimes’; ‘pboffey@nytimes’; ‘lchang@nytimes’; ‘oped@nytimes’ Cc: ‘Daniel Okrent’ ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) Promoting openness and full disclosure https://ahrp.org FYI Friday’s New York Times included the following Editor’s Note on the paper’s Op Ed page:…
British Medical Journal critized for promoting drug cocktail ignoring risks Mon, 14 Jul 2003 The push toward adopting a radical cholesterol lowering strategy, including the use of statin drugs was given a shot in the arm when the British Medical Journal (BMJ) published an article– endorsed by its editor–promoting the…
Statin-Cholesterol Guidelines–Industry influenced? Wed, 14 Jul 2004 Scientific journal editors are scrambling about how to react to bad publicity emanating from public disclosure that the scientific reports they have published are likely to be biased because the authors’ had financial ties to the companies whose drugs / devices they report…
ALLIANCE FOR HUMAN RESEARCH (AHRP) 212-595-8974 FAX: 212-595-9086 Advance Directive Re: Research You Have a Right to Say "Yes" or "No" For your protection, AHRP recommends: Prepare an "Advance Directive" before you enter a hospital, in the event that you become incapacitated or mentally incapable of making informed, reasoned and…
Foster children AIDS Drug-Vaccine Experiments-Editorial – OpEd Sun, 22 May 2005 An editorial in the Toledo Blade, “Pediatric Shame,” expresses the moral indignation of the community upon learning that prestigious medical research Institutions nationwide exploited the vulnerability of children in foster care to test experimental AIDS drugs and vaccines: “in…
AHRP Position Statement on Mental Health Screening – FDA Hearing Re: Drug Advertising Wed, 02 Nov 2005 FDA is holding public hearings (Nov 1, 2) Re: Direct-to-Consumer Promotion of Medical Products at: National Transportation Safety Board Boardroom and Conference Center 429 L’Enfant Plaza, SW., Washington, DC 2 Time: 9:00 –5:00….
